Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientif...(ertainties including those discussed bel...),Health

Date:10/16/2009

ertainties, including those discussed below and more fully described in the Securities and Exchange Commission (SEC) reports filed by Amgen, including Amgen's most recent annual report on Form 10-K and most recent periodic reports on Form 10-Q and Form 8-K. Please refer to Amgen's most recent Forms 10-K, 10-Q and 8-K for additional information on the uncertainties and risk factors related to our business. Unless otherwise noted, Amgen is providing this information as of Oct. 16, 2009 and expressly disclaims any duty to update information contained in this news release.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be
'/>"/>

SOURCE Amgen Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
2. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Tuesday, October 27
3. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Monday, October 26
4. Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25
5. Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24
6. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
7. PolyOne Presented with Frost & Sullivan Medical Product Award
8. CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
9. Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
10. Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the Tipping Point in Treating Pressure Ulcers
11. CRF announces late breaking trials to be presented at TCT 2009 in San Francisco